$GMAB News
Last published 3h ago
- 3h agoGMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsGlobeNewswireCompany Announcement
- 1d agoGMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsGlobeNewswireCompany Announcement
- 1d agoGMABCapital Increase in Genmab as a Result of Employee Warrant ExerciseGlobeNewswireCompany Announcement
- 1w agoGMABABBVMRKJNJ+4A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledCNBCGenmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
- 2w agoGMABGenmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck CancerBusiness WirePhase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing the risk of death by 50% in patients with PD-L1 positive head and neck squamous
- 2w agoGMABGenmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck CancerGlobeNewswireCompany Announcement COPENHAGEN, Denmark; October 28, 2026 Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing the risk of death by
- 2w agoGTBPMRNAIOVAGMAB+1Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment MarketGlobeNewswireNEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are
- 2w agoGMABGenmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaBusiness WireMedian overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (r/m
- 2w agoGMABGenmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal CancerBusiness WirePetosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces the ongoing
- 2w agoGMABINCYGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness WirePhase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (NASDAQ:GMAB) and Incyte (NASDAQ:INCY)
- 2w agoINCYGMABIncyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness WirePhase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Incyte (NASDAQ:INCY) and Genmab A/S (NASDAQ:GMAB) today
- 2w agoGMABGenmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian CancerBusiness WirePhase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator’s choice
- 2w agoGMABGenmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian CancerGlobeNewswireCompany Announcement COPENHAGEN, Denmark; October 23, 2026 Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with
- 4w agoEXELGMABONCYRVMD+1Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaPR NewswireSAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with
- 4w agoGMABGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026GlobeNewswireCompany Announcement Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech,
- 1mo agoABBVGMABAbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaPR NewswireAbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed...
- 1mo agoGMABABBVGenmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaBusiness WireEPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline
- 1mo agoGMABGenmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian CancerBusiness WireTreatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer
- 3mo agoGMABABBVGenmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Business WireGenmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) today provided clarification
- 3mo agoGMABGenmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026GlobeNewswireCompany Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech,
- 4mo agoGMABGenmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness WireTEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a
- 4mo agoGMABGenmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free SurvivalBusiness WireCompany Announcement Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in
- 4mo agoGMABGenmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free SurvivalGlobeNewswireCompany Announcement Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in
- 4mo agoGMABMajor Shareholder AnnouncementGlobeNewswireCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis
- 5mo agoGMABGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Business WireResults from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ineligible for
- 5mo agoGMABGenmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PatientsBusiness WireFindings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups in this trial of
- 5mo agoGMABGenmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 CongressBusiness WireTwenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three
- 6mo agoGMABMajor Shareholder AnnouncementGlobeNewswireCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis
- 7mo agoGMABMajor Shareholder AnnouncementGlobeNewswireCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis
- 7mo agoGMABGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026GlobeNewswireCompany Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech,
- 7mo agoGMABGenmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian CancerBusiness WirePhase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The ongoing Phase 3
- 7mo agoGMABMajor Shareholder AnnouncementGlobeNewswireCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis
- 8mo agoGMABGenmab Publishes 2025 Annual ReportGlobeNewswireCompany Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial
- 9mo agoONCYABBVGMABADCT+1$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command PremiumPR NewswireThe oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This...
- 9mo agoGMABGenmab Announces Net Sales of DARZALEX® (daratumumab) for 2025GlobeNewswireCompany Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN,
- 9mo agoGMABGenmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)GlobeNewswireCompany Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S
- 10mo agoGMABGenmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial IntelligenceBusiness WireSupports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines to patients Genmab A/S (NASDAQ:GMAB) announced today a partnership
- 10mo agoGMABGenmab Portfolio Prioritization UpdateBusiness WireCompany Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab's late‑stage pipeline and
- 10mo agoGMABGenmab Portfolio Prioritization UpdateGlobeNewswireCompany Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio reviewDecision reflects prioritization of higher‑impact opportunities across Genmab's late‑stage pipeline and
- 10mo agoGTBPREGNGMABAUTL+1Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030PR NewswireUSA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer...
- 11mo agoGMABMRUSGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodBusiness WireCompany Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by end of
- 11mo agoGMABMRUSGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodGlobeNewswireCompany Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolioTransaction anticipated to be accretive to Genmab's EBITDA by end of 2029
- 11mo agoGMABGenmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)Business WireTwo-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those
- 11mo agoGMABGenmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular LymphomaBusiness WireTrial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clinically meaningful reduction in the risk of disease progression or
- 11mo agoGMABGenmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)Business WireNew two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FL Latest EPCORE DLBCL-3 trial results
- 11mo agoGMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsGlobeNewswireCompany Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (NASDAQ:GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document
- 11mo agoGMABGenmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness WireCompany Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting In the Phase 3
- 11mo agoGMABGenmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular LymphomaGlobeNewswireCompany Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line settingIn the Phase 3
- 1y agoGMABGenmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual MeetingBusiness WireMore than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of
- 1y agoGMABGenmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial CancerBusiness WireUpdated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless